STEPHANIE SANDERS DENIUS: Open Payments
NPI 1881667327 · ARNOLD, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,282 in 55 payments from 16 companies in 2025. Trend: 2023 $727 · 2024 $730 · 2025 $1,282
Food & beverage: $1,282
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $408 |
| Lilly USA, LLC | 11 | $183 |
| ABBVIE INC. | 8 | $167 |
| Madrigal Pharmaceuticals | 1 | $108 |
| Exact Sciences Corporation | 3 | $66 |
| AstraZeneca Pharmaceuticals LP | 3 | $59 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $52 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| PFIZER INC. | 2 | $34 |
Products named: Ozempic, Rybelsus, MOUNJARO, REZDIFFRA, Wegovy, VRAYLAR, JARDIANCE, XIFAXAN.
Industry payments across MD — which companies pay providers there.
